22 min listen
A Procedural Therapy Seeks to Address Type 2 Diabetes at Its Root Cause
FromThe Bio Report
ratings:
Length:
31 minutes
Released:
Aug 19, 2021
Format:
Podcast episode
Description
Type 2 diabetes affects nearly 500 million people worldwide and more than 34 million people in the United States. The disease carries an elevated risks of heart attack, stroke, and other serious complications. Fractyl Health believes the approach to treating diabetes by controlling blood sugar levels and other symptoms has been faulty. Research has implicated a critical role the first section of intestine, known as the duodenum, plays in the condition and the company has developed a minimally invasive endoscopic procedure that it believes can correct the problem. We spoke to Harith Rajagopalan, CEO of Fractyl Health, about the company’s experimental procedural therapy to target the root cause of diabetes, how it works, and the path forward to commercialization.
Released:
Aug 19, 2021
Format:
Podcast episode
Titles in the series (100)
The Year in Biotech So Far and What’s Ahead: The biotech sector surged in the first half of the year despite volatile markets. M&A and financing continued to be robust as EvaluatePharma weighed in with its Pharma & Biotech Half-Year Report. We spoke to Jonathan Gardner, deputy news editor of EP... by The Bio Report